Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Receivables - Accured (2022 - 2024)

Kezar Life Sciences (KZR) has disclosed Receivables - Accured for 3 consecutive years, with $589000.0 as the latest value for Q3 2024.

  • Quarterly Receivables - Accured changed N/A to $589000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $589000.0 through Sep 2024, changed N/A year-over-year, with the annual reading at $695000.0 for FY2023, 10.21% down from the prior year.
  • Receivables - Accured hit $589000.0 in Q3 2024 for Kezar Life Sciences, up from $374000.0 in the prior quarter.
  • In the past five years, Receivables - Accured ranged from a high of $774000.0 in Q4 2022 to a low of $374000.0 in Q2 2024.
  • Historically, Receivables - Accured has averaged $616000.0 across 3 years, with a median of $648000.0 in 2024.
  • Biggest YoY gain for Receivables - Accured was 10.21% in 2023; the steepest drop was 10.21% in 2023.
  • Year by year, Receivables - Accured stood at $774000.0 in 2022, then fell by 10.21% to $695000.0 in 2023, then dropped by 15.25% to $589000.0 in 2024.
  • Business Quant data shows Receivables - Accured for KZR at $589000.0 in Q3 2024, $374000.0 in Q2 2024, and $648000.0 in Q1 2024.